Pinnacle Medicines added $89 million to advance oral peptide drug candidates designed to combine biologic-like properties with small-molecule-style dosing. The startup says its lead program, developed with OrbiMed-incubated incubation support, is on track to enter the clinic in asthma and chronic obstructive pulmonary disease. The funding underscores investor appetite for platform approaches that aim to avoid injections while preserving potency. For developers, the key near-term milestone will be demonstrating consistent oral exposure and pharmacodynamic activity for peptides expected to behave more like biologics. Pinnacle’s pipeline emphasis on “properties of injectable biologics” suggests a strategy built around overcoming common barriers that have historically limited oral peptide development, particularly around stability and systemic delivery.